ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 350

Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies

Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abatacept, Cardiovascular disease, inflammation and tocilizumab, NT-proBNP

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker for HF. Recently, a study demonstrated that NT-proBNP levels in RA patients decreased under TNF-blocking therapy. It is unknown whether this is also observed in biologics with other mode of actions. We evaluated the effects of abatacept and tocilizumab therapy on NT-proBNP levels.

 

Methods: In 34 RA consecutive patients starting with abatacept (10 mg/kg every 4 weeks) and 14 RA consecutive patients starting with tocilizumab (8 mg/kg every 4 weeks), disease activity parameters and serum samples were collected at baseline and after 12 weeks of therapy. Clinical response was assessed using EULAR response criteria. Responding patients comprised both good and moderate EULAR responders. NT-proBNP levels were measured by the Elecsys 2010 electrochemiluminescence method (Roche diagnostics). For statistical analyses t-tests, Mann-Whitney U tests and linear regression were used.

 

Results: NT-proBNP levels did not change significantly after 12 weeks (p=0.6) and there were no significant differences in NT-proBNP levels at baseline or after 12 weeks of treatment between the tocilizumab and abatacept group (p=0.16 and p=0.3, respectively). 34 patients (71%) were EULAR responders, (6=12% good, 28=88% moderate) and 14 patients (29%) were non-responders. Baseline DAS28, CRP and BSE were higher, though not significantly, in responders compared to non-responders (table). Baseline NT-proBNP levels were higher in responders versus non-responders (p=0.044). Change in NT-proBNP levels after 12 weeks of treatment was significantly different between responders and non-responders (p=0.002), with decreasing NT-proBNP levels in responders and increasing levels in non-responders.

 

Conclusion: There was a remarkable difference in the course of NT-proBNP levels between EULAR responders and non-responders, as responders started with higher baseline levels which decreased significantly under both abatacept and tocilizumab treatment, while in contrast the NT-proBNP levels of non-responding patients increased. These findings indicate favourable effects of abatacept and tocilizumab on cardiac function in RA patients responding to treatment and underscore the importance of tight control of systemic inflammation in order to decrease CV risk.

 

 

         


Disclosure:

I. A. M. van den Oever,

BMS,

8;

M. T. Nurmohamed,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-of-inflammation-with-abatacept-and-tocilizumab-results-in-lower-n-terminal-pro-brain-natriuretic-peptide-levels-in-patients-with-rheumatoid-arthritis-results-from-prospective-cohort-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology